Interestingly, sotagliflozin, a dual SGLT2/SGLT1 inhibitor, significantly reduced the total risk of fatal or non-fatal stroke by 34% (HR, 0.66; 95% CI, 0.48–0.91) in the placebo-controlled, phase III SCORED trial performed in patients with T2DM and CKD [25]. Here, SLC5A2 is linked to type 2 diabetes mellitus.